Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04278781 · ClinicalTrials.gov registry record · Phase 2
AG-120 in People With IDH1 Mutant Chondrosarcoma
A Phase 2 study of Chondrosarcoma and IDH1 Gene Mutation, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
- 5
- Study locations
NCT04278781 is a Phase 2 study of Chondrosarcoma and IDH1 Gene Mutation that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 6 participants, below the 128-participant average among 11 other Chondrosarcoma trials with a reported enrollment target (95% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT04278781, a Phase 2 study of Chondrosarcoma and IDH1 Gene Mutation, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is being done to see whether AG-120 is an effective and safe treatment for people with advanced/metastatic or recurrent chondrosarcoma that has IDH1 mutation.
Conditions Studied
Interventions
- DRUG AG-120
Study Locations (5)
New York
- Columbia University (Specimen Analysis Only) - New York
- Memorial Sloan Kettering Cancer Center - New York
Maryland
- Johns Hopkins Hospital (Data Collection Only) - Baltimore
Ohio
- The Ohio State University (Data Collection Only) - Columbus
Texas
- MD Anderson Cancer Center (Data Collection Only) - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-03-04 |
| Est. Completion | 2026-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04278781
The ClinicalTrials.gov registry entry for NCT04278781 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 128-participant average among 11 other Chondrosarcoma trials with a reported enrollment target (95% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Chondrosarcoma appearing as the primary indexed condition, and to 1 intervention - of which AG-120 is the first listed.
NCT04278781 reports 5 study locations spanning 4 distinct geographic areas - top geographies include New York, Maryland, Ohio.
Frequently Asked Questions
What is clinical trial NCT04278781 about?
NCT04278781 is a clinical study titled "AG-120 in People With IDH1 Mutant Chondrosarcoma". This study is being done to see whether AG-120 is an effective and safe treatment for people with advanced/metastatic or recurrent chondrosarcoma that has IDH1 mutation.
What is the current status of trial NCT04278781?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2020-03-04. Estimated completion is 2026-03.
What conditions does trial NCT04278781 study?
This clinical trial studies the following conditions: Chondrosarcoma, IDH1 Gene Mutation, Chondrosarcoma, Grade 2, Chondrosarcoma, Grade 3.
What interventions are being tested in trial NCT04278781?
The interventions under investigation include: AG-120 (DRUG).
Who is sponsoring clinical trial NCT04278781?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04278781 being conducted?
This trial has 5 study locations across Maryland, New York, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chondrosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
RECRUITING · Phase 2
-
Proton Beam Therapy for Chondrosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
COMPLETED · Phase 2
-
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
RECRUITING · Phase 1
-
Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.